Found: 12
Select item for more details and to access through your institution.
Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
- Published in:
- PLoS ONE, 2015, v. 10, n. 8, p. 1, doi. 10.1371/journal.pone.0134341
- By:
- Publication type:
- Article
The Pharmacological Chaperone AT2220 Increases the Specific Activity and Lysosomal Delivery of Mutant Acid Alpha-Glucosidase, and Promotes Glycogen Reduction in a Transgenic Mouse Model of Pompe Disease.
- Published in:
- PLoS ONE, 2014, v. 9, n. 7, p. 1, doi. 10.1371/journal.pone.0102092
- By:
- Publication type:
- Article
Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb<sub>3</sub>) in Fabry Transgenic Mice and in the Plasma of Fabry Patients.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0057631
- By:
- Publication type:
- Article
The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease.
- Published in:
- PLoS ONE, 2012, v. 7, n. 7, p. 1, doi. 10.1371/journal.pone.0040776
- By:
- Publication type:
- Article
Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.
- Published in:
- Molecular Therapy, 2015, v. 23, n. 7, p. 1138, doi. 10.1038/mt.2015.62
- By:
- Publication type:
- Article
The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of β-glucosidase.
- Published in:
- FEBS Journal, 2010, v. 277, n. 7, p. 1618, doi. 10.1111/j.1742-4658.2010.07588.x
- By:
- Publication type:
- Article
Identification and Characterization of Pharmacological Chaperones to Correct Enzyme Deficiencies in Lysosomal Storage Disorders.
- Published in:
- Assay & Drug Development Technologies, 2011, v. 9, n. 3, p. 213, doi. 10.1089/adt.2011.0370
- By:
- Publication type:
- Article
Co-administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human α-Galactosidase A Tissue Uptake and Improves Substrate Reduction in Fabry Mice.
- Published in:
- Molecular Therapy, 2012, v. 20, n. 4, p. 717, doi. 10.1038/mt.2011.271
- By:
- Publication type:
- Article
The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease.
- Published in:
- Molecular Therapy, 2010, v. 18, n. 1, p. 23, doi. 10.1038/mt.2009.220
- By:
- Publication type:
- Article
A pharmacogenetic approach to identify mutant forms of α-galactosidase a that respond to a pharmacological chaperone for Fabry disease.
- Published in:
- Human Mutation, 2011, v. 32, n. 8, p. 965, doi. 10.1002/humu.21530
- By:
- Publication type:
- Article
The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase.
- Published in:
- Human Mutation, 2009, v. 30, n. 12, p. 1683, doi. 10.1002/humu.21121
- By:
- Publication type:
- Article
Lysosomal Dysfunction in a Mouse Model of Sandhoff Disease Leads to Accumulation of Ganglioside-Bound Amyloid-ß Peptide.
- Published in:
- Journal of Neuroscience, 2012, v. 32, n. 15, p. 5223, doi. 10.1523/JNEUROSCI.4860-11.2012
- By:
- Publication type:
- Article